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Abstract
Background: Associations between circulating markers of dysglycaemia and coronary heart disease (CHD) risk in people
without diabetes have not been reliably characterised. We report new data from a prospective study and a systematic
review to help quantify these associations.
Methods and Findings: Fasting and post-load glucose levels were measured in 18,569 participants in the population-based
Reykjavik study, yielding 4,664 incident CHD outcomes during 23.5 y of mean follow-up. In people with no known history of
diabetes at the baseline survey, the hazard ratio (HR) for CHD, adjusted for several conventional risk factors, was 2.37 (95%
CI 1.79–3.14) in individuals with fasting glucose $7.0 mmol/l compared to those ,7 mmol/l. At fasting glucose values
below 7 mmol/l, adjusted HRs were 0.95 (0.89–1.01) per 1 mmol/l higher fasting glucose and 1.03 (1.01–1.05) per 1 mmol/l
higher post-load glucose. HRs for CHD risk were generally modest and nonsignificant across tenths of glucose values below
7 mmol/l. We did a meta-analysis of 26 additional relevant prospective studies identified in a systematic review of Western
cohort studies that recorded fasting glucose, post-load glucose, or glycated haemoglobin (HbA1c) levels. In this combined
analysis, in which participants with a self-reported history of diabetes and/or fasting blood glucose $7 mmol/l at baseline
were excluded, relative risks for CHD, adjusted for several conventional risk factors, were: 1.06 (1.00–1.12) per 1 mmol/l
higher fasting glucose (23 cohorts, 10,808 cases, 255,171 participants); 1.05 (1.03–1.07) per 1 mmol/l higher post-load
glucose (15 cohorts, 12,652 cases, 102,382 participants); and 1.20 (1.10–1.31) per 1% higher HbA1c (9 cohorts, 1639 cases,
49,099 participants).
Conclusions: In the Reykjavik Study and a meta-analysis of other Western prospective studies, fasting and post-load glucose
levels were modestly associated with CHD risk in people without diabetes. The meta-analysis suggested a somewhat
stronger association between HbA1c levels and CHD risk.
Please see later in the article for the Editors’ Summary.
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Diabetes is an established risk factor for coronary heart disease
(CHD).Thereisconsiderableinterestinwhethercirculating markers
of glucose metabolism are associated with risk of CHD in people
without diabetes. Various measures of dysglycaemia have been
assessed in long-term studies of CHD, notably: fasting glucose
concentration (an indicator of steady-state glucose metabolism at the
time of measurement); post-load glucose concentration (an indicator
of immediate response to glycaemic stress); and glycated haemoglo-
bin (HbA1c, an indicator of average blood glucose concentration
over the previous 1–3 mo) [1,2]. It has been proposed that markers
of dysglycaemia may be log-linearly and importantly associated with
risk of subsequent vascular disease at all levels (including below the
thresholds defining diabetes) [3–5], but available data are not
conclusive. For example, the US Preventive Services Task Force
recentlystated thatpublishedprospectivedataon fastingglucose and
CHD were ‘‘inconsistent’’ and had ‘‘serious limitations’’ [6].
We report new data from the population-based Reykjavik
prospective study on associations of fasting and post-load glucose
levels with CHD incidence across the range of glucose values. We
also did a systematic review and meta-analysis of tabular data from
26 additional relevant Western cohorts [7–31]. In total, the
current report considers data on 303,961 participants, including
16,982 incident CHD cases.
Methods
Participants in the Reykjavik Study
The Reykjavik study has been described in detail previously [32].
Men born during 1907–1934 and women born during 1908–1935
who were resident in Reykjavik,Iceland and its adjacent communities
on 1 December 1966 were identified in the national population
register and invited to participate during five stages of recruitment
between 1967 and 1991. A total of 8,888 male and 9,681 female
participants without a history of myocardial infarction agreed to take
part (72% response rate). Nurses administered questionnaires, made
physical measurements, recorded an electrocardiogram, and collect-
ed fasting blood samples (taken after $8 h of fasting) at baseline. All
participants have been monitored subsequently by central registries
for occurrence of major cardiovascular morbidity (based on WHO
MONICA [Multinational Monitoring of Trends and Determinants
in Cardiovascular Disease] or similar criteria) or cause-specific
mortality (based on a death certificate with International Classifica-
tion of Diseases [ICD] 9 codes 410–414), with a loss to follow-up of
only about 0.6% to date. During mean follow-up of 23.5 y, nonfatal
MI or fatal CHD was recorded in a total of 4,664 participants, of
whom 4,490 (including 3,088 men and 1,402 women) had no history
ofdiabetesatbaseline.Datawerenotavailableonincidenceofstroke,
diabetes, or microvascular disease. The National Bioethics Commit-
tee and the Data Protection Authority of Iceland approved the study
protocol, and participants gave informed consent.
Laboratory Methods
Fasting glucose measurement was carried out in fresh capillary
whole blood within hours of blood sampling at the initial
examination by a micro method on a Technicon Autoanalyzer
using a modification of the W. S. Hoffman method (coefficient of
variation 4%) and standardised to the Hyland Normal Clinical
Chemistry Control Serum (Nygaard A/S, Oslo) [33]. Post-load
glucose levels were measured 60 and 90 min after ingestion of a
50 g glucose load. Lipid and other measurements involved
standard assays, as previously described [32]. HbA1c measure-
ments were not done.
Statistical Methods
The shapes of associations with CHD risk in the Reykjavik study
were characterized by calculation of hazard ratios (HRs) across
tenths of glucose values, including the full range of glucose values
observed. Cox proportional hazards regression models were
adjusted for age, sex, smoking status, systolic blood pressure, total
cholesterol, and body mass index (BMI). Ninety-five percent
confidence intervals (95% CIs) were estimated from the variances
that reflect the amount of information underlying each group
(including the reference group) [34]. Subsidiary analyses corrected
for regression dilution using serial glucose measurements made in
370 of the participants (mean interval: 12 y) [35]. In 18,333
participants without evidence of diabetes at baseline (i.e., no self-
reported history and fasting blood glucose ,7 mmol/l), HRs for
CHD were calculated per 1 mmol/l higher glucose concentration.
Impaired fasting glucose was defined using published guidelines
[36]. Effect-modification was investigated by formal tests of
interaction.
Systematic Review
Three of the current investigators (NS, RG, and SRKS) sought
prospective studies published between January 1970 and Septem-
ber 2009 that had reported on associations of fasting blood
glucose, post-load glucose, and/or HbA1c with incident CHD.
Details of the search strategies and a flow diagram are provided in
Text S1. Published studies were identified through electronic
searches not limited to the English language (using MEDLINE,
EMBASE, BIOSIS, and the Science Citation Index), by scanning
reference lists of articles identified for all relevant studies (including
review articles), and by hand searching of selected general medical
journals (i.e., BMJ, JAMA, Lancet, NEJM, PLoS Medicine, Annals of
Internal Medicine, Archives of Internal Medicine), cardiovascular/
diabetes journals (i.e., Circulation, Diabetes, Diabetes Care, European
Heart Journal, Journal of the American College of Cardiology), and
epidemiological journals (i.e., American Journal of Epidemiology,
International Journal of Epidemiology). Studies were eligible for
inclusion if they: (1) did not select participants on the basis of
having pre-existing vascular disease; (2) were located in Western
Europe, North America, or Australasia (a restriction to reduce
potential heterogeneity due to factors related to geographical
location, e.g., ethnicity; see Discussion); (3) had more than 1 y of
follow-up; and (4) reported on nonfatal MI (as defined by WHO
MONICA or equivalent criteria, i.e., involving diagnosis based on
clinical symptoms, electrocardiographic abnormalities, and/or
cardiac biomarkers) and/or fatal CHD (defined by ICD criteria).
Eligibility for inclusion of identified studies was considered by two
investigators (RG and SRKS). Any disagreement was resolved by
discussion and, if necessary, by the deciding vote of a third
reviewer (NS).
A request for tabular data was sent to investigators of every
eligible study identified. The following information was sought
(excluding participants with a self-reported history of diabetes
and/or fasting blood glucose $7 mmol/l at baseline), according to
a uniform protocol: number of incident CHD outcomes recorded;
relative risk (RR with 95% CI for CHD per unit higher
dysglycaemia marker, initially after adjustment for age and sex
only and then after additional adjustment for smoking status,
systolic blood pressure, lipid concentrations, and BMI); the content
of the glucose load and interval before post-load venipuncture;
number of participants with resurvey measurements; interval
between such measurements; and degree of long-term within-
person variability of dysglycaemia markers (Table S1). Accuracy of
the information supplied was cross-checked against published
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achieved through consultation with study investigators.
Meta-analysis
Summary RRs for CHD per unit higher dysglycaemia marker
were calculated by pooling study-specific estimates using a random
effects model. Analyses involved only within-study comparisons.
As regards units of analysis used, 1 mmol/l higher fasting glucose
corresponds approximately to 1-standard deviation (SD) higher
levels; 1 mmol/l higher post-load glucose corresponds approxi-
mately to 2-SD higher levels; and 1% higher HbA1c corresponds
approximately to 1-SD higher levels. Consistency of findings was
assessed by standard x
2 tests and the I
2 statistic [37]. Diversity at
the study level was investigated by grouping studies by recorded
characteristics and by meta-regression (including study size and




Baseline conventional risk factors were significantly higher in
those who subsequently recorded incident CHD than in non-cases,
as were fasting and 1-h post-load glucose levels (Table S2). Fasting
and 1-h post-load glucose levels were each significantly correlated
with several conventional riskfactorsandwith each other (TableS3).
In people without diabetes at baseline, serial measurements yielded
intra-class correlation coefficients of 0.61 (95% CI 0.54–0.67) for
fasting bloodglucose,0.50(0.42–0.57)for1-h post-load glucose,0.59
(0.51–0.67) for total cholesterol, and 0.65 (0.54–0.77) for systolic
blood pressure. In people who had no history of diabetes at baseline,
HR for CHD—adjusted for age, sex, recruitment period, smoking
status, systolic blood pressure, total cholesterol, and BMI (hence-
forth, ‘‘adjusted HR’’)—was 2.37 (1.79–3.14) in those with fasting
glucose $7.0 mmol/l compared with those ,7.0 mmol/l. (HR was
1.67 [1.36–2.02] with fasting glucose $6.1 mmol/l compared with
those ,6.1 mmol/l, a definition of diabetes proposed for studies
involving capillary whole blood samples [39].) In analyses across
tenths of fasting glucose values, adjusted HRs for CHD were
generally weak and nonsignificant at levels below 7 mmol/l
(Figure 1). Findings were broadly similar for 1-h post-load glucose
levels (Figure 2) and in analyses that: adjusted for age and sex only
(Figure S1); corrected for regression dilution (Figure S2); assessed 90-
min post-load glucose (available upon request from NS).
In people who had no history of diabetes and fasting glucose
,7.0 mmol/l at baseline, adjusted HR for CHD was 0.95 (0.89–
1.01) per 1 mmol/l higher fasting glucose and 1.03 (1.01–1.05) per
1 mmol/l higher 1-h post-load glucose. Similar findings were
observed in analyses that: explored HRs in a range of clinically
relevant subgroups (Figure S3); assessed HRs in 5-y intervals of
follow-up(available uponrequest);orexcludedpeoplewithpost-load
glucose levels $11.1 mmol/l (available upon request). Compared
with individualswith fasting glucose,5.6 mmol/l, adjusted HRs for
CHD were: 1.27 (0.96–1.68) with fasting glucose levels 6.1–
7.0 mmol/l and 1.08 (0.87–1.33) with fasting glucose levels 5.6–
6.1 mmol/l (i.e., corresponding to categories of fasting glucose
concentration used to define impaired fasting glucose).
Meta-analysis
Thirty-five potentially eligible prospective studies were identi-
fied, including the present Reykjavik study. Of these studies, 27
contributed data to the current analysis, yielding 303,961
participants, including 16,982 incident CHD cases (Table S4).
This information constitutes .85% of the relevant incident CHD
cases identified (Text S1 lists the noncontributing studies).
Fourteen of the contributing studies were based in Western
Europe, ten in North America, and three in Australia. All
recruited participants from population registers or occupational
settings. Fifty-six percent of the participants were male, and most
were middle-aged and of European descent. For fasting glucose,
there were 23 contributing studies, yielding 255,171 participants
and 10,808 incident CHD cases. All studies used standard glucose
assay methods and reported generally similar mean glucose values
(Table S4), with four studies involving whole blood samples and 19
plasma or serum. For post-load glucose, there were 15 contrib-
uting studies, yielding 102,382 participants and 12,652 cases. Ten
of these studies measured glucose 2 h after a 75 g load and five
studies used other methods. For HbA1c, there were nine
contributing studies, yielding 49,099 participants and 1,639 cases.
Seven studies [8,11,13,17,23,30] provided information on long-
term serial measurements, yielding weighted intra-class correlation
coefficients of 0.67 (0.66–0.69) for fasting glucose (7,834 partici-
pants, mean interval 3.5 y), 0.48 (0.46–0.50) for post-load glucose
(5,617 participants, 3.5 y), and 0.69 (0.68–0.70) for HbA1c (6,370
participants, 4 y). Combined RRs, adjusted for age and sex only,
were: 1.12 (1.06–1.18) per 1 mmol/l higher fasting glucose; 1.08
(1.04–1.11) per 1 mmol/l higher post-load glucose; and 1.34 (1.24–
1.44) per 1% higher HbA1c. Corresponding RRs adjusted for
several conventional risk factors were: 1.06 (1.00–1.12) with fasting
glucose; 1.05 (1.03–1.07) with post-load glucose; and 1.20 (1.10–
1.31)with HbA1c(Figure3).There washeterogeneityineachRR(I
2
of 82% [74–88], 88% [83–93], and 42% [0–69], respectively), but
little of it was explained by characteristics recorded (Figure 4). For
fasting glucose, RRs were very similar in studies involving whole
blood samples and in those with plasma or serum (1.05 versus 1.06).
For post-load glucose, RRs were very similar in studies measuring
glucose 2 h after a 75 g glucose load and in those in studies using
other methods (1.05 versus 1.05). Subsidiary analyses that omitted
any particular study did not materially alter the findings (e.g.,
omission of the Reykjavik study yielded adjusted RRs of 1.06 [1.00–
1.12] with fasting glucose and 1.05 [1.03–1.08] with post-load
glucose; and omission of the San Antonio Heart Study, which had
unusually narrow CIs given its size, yielded adjusted RRs of 1.02
[0.99–1.06] with fasting glucose and 1.04 [1.02–1.07] with post-
load glucose). There was no good evidence of small study effects
(e.g., Egger test p.0.1 for each marker assessed). Literature-based
analysesyielded broadlysimilarRRswithfastingglucose inthenon-
contributing studies to those reported here (Text S1).
Discussion
The current data indicate that fasting and post-load glucose and
HbA1c each have reasonably high degrees of long-term within-
person reproducibility (i.e., broadly comparable to such repro-
ducibility values for total cholesterol and systolic blood pressure).
Figure 1. Risk of CHD across tenths of baseline fasting glucose levels in the Reykjavik Study. All hazard ratios are adjusted for age, sex,
recruitment period, smoking status, systolic blood pressure, total cholesterol, and BMI, and all are compared to individuals in the middle tenth of the
distribution. The grey area denotes the 95% CI of the reference group. Analyses involved the full range of glucose values (i.e., including individuals
with glucose levels in the diabetic range). To limit any bias related to having a diagnosis of diabetes (e.g., medication use, lifestyle changes), however,
individuals with a known history of diabetes at the baseline survey were excluded.
doi:10.1371/journal.pmed.1000278.g001
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prospective studies involving a total of .300,000 people (<17,000
incident CHD cases) indicate that fasting glucose concentration is
modestly associated with CHD risk in people without diabetes, i.e.,
RR for CHD was about 1.06 per 1 mmol/l higher fasting glucose.
Furthermore, in the Reykjavik prospective study, RRs were
generally modest and nonsignificant across glucose values below
the diabetes definition (i.e., fasting glucose ,7 mmol/l). We
observed similar results in relation to post-load glucose. The
current findings contrast with those from some smaller previous
studies, which have suggested that glucose values are log-linearly
and more strongly associated with CHD risk (including at glucose
values lower than those defining diabetes). Because previous
epidemiological estimates have influenced scientific guideline
statements [40], clinical risk assessment strategies [41], burden of
disease estimates [42], and public health policy recommendations
[43], it may be helpful to review such efforts in the light of the
current updated epidemiological evidence. Careful consideration
may also need to be given to the design and interpretation of trials
of CHD prevention using glucose-lowering agents in people
without diabetes, as the current findings suggest that trial sample
sizes required may be larger than previously anticipated [44–47].
In contrast with findings for glucose concentration, the current
meta-analysis has indicated a RR for CHD of 1.20 per 1% higher
HbA1c in people without diabetes. Although RRs for CHD appear
stronger with HbA1c than those with glucose concentration, this
possibility requires careful interpretation because: (1) the compar-
ison isanindirectone(i.e.,fasting glucoseandHbA1cmeasurements
were typically not made in the same participants) and (2) fewer than
one-fifth as many incident CHD cases have been reported with
HbA1c as with glucose concentration (so associations with HbA1c
cannot be quantified as reliably as those with glucose levels).
Nevertheless, because the current data suggest that fasting glucose
and HbA1c have similar levels of within-person variability over
several years, such variability seems unlikely to account for
differences seen in RRs with different measures of dysglycaemia.
It remains uncertain whether HbA1c is a more informative measure
of dysglycaemia than are fasting or post-load glucose levels, more
accuratelyreflects processesrelevant to vascular damage inresponse
to glycation, or some combination of these possibilities [2,48].
The strengths and potential limitations of this study merit
consideration. For fasting glucose, the Reykjavik study involves
more incident CHD cases than in any previous prospective study. It
identifiedparticipantsinpopulationregisters,achievedhighresponse
and follow-up rates, and entailed robust ascertainment of incident
MIandfatalCHD.Wehavedemonstratedthevalidityoftheglucose
measurements in capillary whole blood samples by showing: the
expected strong associations of fasting glucose levels with CHD in
people with values $7.0 mmol/l; long-term within-person consis-
tency of glucose concentration comparable to that for systolic blood
pressure and total cholesterol concentration; and similar findings as
in previous studies that used plasma or serum. For post-load glucose,
RRs in the Reykjavik study (involving assessment 1 h after ingestion
of a 50 g glucose load) were very similar to RRs in studies involving
assessment 2 h after ingestion of a 75 g glucose load.
As findings in the Reykjavik study were reinforced by a meta-
analysis of tabular data from 26 other long-term prospective
studies located in ten Western countries, it increases the likelihood
that these results can be extrapolated, at least to other Western
populations. Although our review focused only on Western cohorts
to reduce heterogeneity, it may be relevant to note that the largest
available prospective study in East Asia (<3,100 incident MI
outcomes) has reported similar findings to those described here,
concluding that fasting glucose concentration has no clear
association with MI risk below the diabetes definition [49]. Our
meta-analysis included .85% of the relevant data identified by the
systematic review (and a literature-based sensitivity analyses of
noncontributing studies yielded broadly similar findings). Although
we noted heterogeneity, it was not explained by the characteristics
recorded here. Because some previous reviews did not consistently
exclude people with diabetes at baseline [3,4] or involved only
fatal CHD [5], it is difficult to compare their RRs directly with the
RRs observed here. A more detailed consideration of available
prospective studies, perhaps on the basis of combination of
individual participant data, will enable more reliable analyses
under a broader range of circumstances and a more detailed
investigation of potential sources of diversity.
Conclusions
In people without diabetes, fasting and post-load glucose levels
were modestly associated with CHD risk. Associations of HbA1c
with CHD risk in such people appeared somewhat stronger.
Scientific guidelines, policies, and trial designs premised on the
existence of strong, log-linear associations of fasting and post-load
glucose concentration with CHD risk may benefit from review in
light of these epidemiological findings.
Supporting Information
Figure S1 Risk of coronary heart disease across tenths of
baseline fasting glucose in the Reykjavik Study, adjusted for age
and sex only.
Found at: doi:10.1371/journal.pmed.1000278.s001 (0.04 MB
DOC)
Figure S2 Risk of coronary heart disease across tenths of usual
fasting glucose in the Reykjavik Study.
Found at: doi:10.1371/journal.pmed.1000278.s002 (0.04 MB
DOC)
Figure S3 Hazard ratios for coronary heart disease per 1 mmol/
l higher fasting and 1-h post-load glucose concentration in
individuals without diabetes in the Reykjavik Study, grouped by
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Found at: doi:10.1371/journal.pmed.1000278.s003 (0.04 MB
DOC)
Table S1 Copy of form used to seek tabular data for the updated
meta-analysis in the present report.
Found at: doi:10.1371/journal.pmed.1000278.s004 (0.04 MB
DOC)
Table S2 Baseline characteristics of study participants at the
initial examination in the Reykjavik Study.
Found at: doi:10.1371/journal.pmed.1000278.s005 (0.04 MB
DOC)
Figure 2. Risk of CHD across tenths of baseline 1 h post-load glucose levels in the Reykjavik Study. All hazard ratios are adjusted for age,
sex, recruitment period, smoking status, systolic blood pressure, total cholesterol, and BMI, and all are compared to individuals in the middle tentho f
the distribution. The grey area denotes the 95% CI of the reference group. Analyses involved the full range of glucose values (i.e., including
individuals with glucose levels in the diabetic range). To limit any bias related to having a diagnosis of diabetes (e.g., medication use, lifestyle
changes), however, individuals with a known history of diabetes at the baseline survey were excluded.
doi:10.1371/journal.pmed.1000278.g002
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Note Added in Proof
Investigators of an additional study of fasting glucose concentra-
tion and CHD [50], involving a further 6,447 participants and 862
incident CHD cases, provided tabular data while this article was in
proof. After addition of these data to the meta-analysis, the
combined adjusted relative risk for CHD was 1.05 (1.00–1.10) per
1 mmol/l higher fasting glucose concentration (24 cohorts, 11,670
cases, 261,618 participants).
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Background. Among people diagnosed with type 2
diabetes mellitus (the commonest type of diabetes
worldwide), poor management or lack of appropriate
treatment can lead to long-term complications resulting
from persistently high sugar levels in the blood. The long-
term complications of type 2 diabetes are generally divided
into two main groups: microvascular problems (such as
nerve damage, kidney disease, and eye disorders), and
macrovascular disease (such as heart disease, strokes, and
peripheral vascular disease). A major goal of diabetes
treatment is to keep glucose control as normal as possible
through diet, weight control, exercise, and pharmacological
treatments. However, it is unclear whether the link between
high blood sugar and macrovascular disease (principally
heart disease and strokes) also holds for people who have
slightly higher than normal blood sugar levels, but in whom
this level does not reach the diabetic threshold. Some
previous research studies have suggested that a continuous
relationship exists between blood sugar level and the risk of
heart disease across the spectrum, i.e., below the diabetic
threshold as well as above it. If such a relationship were
confirmed this might have important implications for the
management of high blood sugar levels even among people
who would not normally meet the usual definition for a
diagnosis of diabetes (the ‘‘diabetic threshold’’).
Why Was This Study Done? Studies which examine the
risk of serious, but relatively common, outcomes (such as a
nonfatal heart attack or fatal heart disease), often suffer from
insufficient statistical power: a large number of participants
need to be recruited, and followed up over a long time, to
find out whether certain factors measured at baseline (e.g.,
fasting glucose) are indeed associated with a particular
outcome (e.g., heart attack) or not during follow up. Given
the inconclusive nature of some previous studies in this area,
the researchers who carried out this work wanted to gather
evidence from a large prospective cohort, and a reappraisal
of all existing evidence, in relation to the possible link
between high blood sugar and risk of heart disease in people
without diabetes.
What Did the Researchers Do and Find? In this study,
the researchers report results from a prospective population-
based study (in which participants are followed forward in
time) from Reykjavik, Iceland. In the study, men and women
without history of heart disease aged between 31 and 57 in
1966 were first invited to join the cohort, and were followed
forward in time using national registries that recorded
deaths (and causes of death), and incidence of heart disease.
A total of 8,888 male and 9,681 female participants were
recruited. At baseline, laboratory measurements were taken
to record blood sugar levels using two different methods:
fasting blood glucose and post-load glucose. Among the
group of participants, 4,664 people were recorded as having
either a nonfatal heart attack or fatal heart disease, during
approximately 23 years of follow-up. In addition, the
researchers attempted to identify from the published
medical literature previous prospective studies conducted
in Western populations that had looked at the association
between blood sugar levels and risk of coronary heart
disease. They requested, and obtained, re-analyses of data
conducted in accordance with a common protocol for most
of the identified studies and then analysed these, together
with the results of the Reykjavik cohort, to produce a
summary estimate (meta-analysis) of the association
between blood sugar levels and risk of coronary heart
disease in people without diabetes.
In the Reykjavik cohort, the researchers confirmed an
increased risk of coronary heart disease among individuals
with blood sugar above the diabetic threshold, as compared
to those below it. However, when they looked at blood sugar
in people below the diabetic threshold, they found no
evidence that higher levels were strongly linked with greater
risk of coronary heart disease. This held for both methods of
measuring blood sugar levels (fasting and post-load).
In the meta-analysis, the researchers obtained data for 27
different studies, comprising 303,961 participants and 16,982
cases of heart disease. In this meta-analysis, very small
increases in risk of heart disease were found with higher
levels of blood sugar, when measured using fasting blood
glucose or post-load glucose. However, studies using
glycated haemoglobin (a measure of average sugar levels
over the past 1–3 months or so) found this measure to be
associated with a somewhat higher risk of heart disease.
What Do these Findings Mean? In this prospective
cohort and wider meta-analysis, the researchers did not find
evidence of a strong or continuous association between
blood sugar levels and risk of heart disease amongst people
without diabetes. The prospective study, and analysis of
other cohorts, was large, but only looked at participants of
European decent, so it is not clear whether the findings will
also hold for non-European groups.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000278.
N Information is available from the US National Diabetes
Information Clearinghouse about diabetes, heart disease,
and stroke
N Centers for Disease Control provides information for the
public and professionals about diabetes on their diabetes
minisite
N Medline Plus encyclopedia has an entry about coronary
heart disease
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